ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2020
Is the Log-Rank and Hazard Ratio Test/Estimation the Best Approach for Primary Analysis for All Trials?
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Design and Analysis of Randomized Clinical Trials With Average Hazard: Practical Guidance and Tools for Implementation.Statistics in medicine · 2026Article
- Regression models for average hazard.Biometrics · 2024Article
- Are restricted mean survival time methods especially useful for noninferiority trials?Clinical trials (London, England) · 2021Article
- Outcomes at 5 years in patients with severe aortic stenosis: reviewing current information using the restricted mean survival time.American journal of cardiovascular disease · 2020Review
Corrections and comments
- Commented on by
- Comment on
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
32315272What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.